Across TCGA pan-cancer cohorts, OR4F4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR4F4 data layer compared with 10 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR4F4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4F4 expression acts as an unfavorable survival marker.
SKCM are the cancer types where OR4F4 Mutation most reproducibly stratifies survival.